We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Biomarkers Aid Detection of Prodromal Alzheimer Disease

By LabMedica International staff writers
Posted on 17 Jan 2012
Print article
Cerebrospinal fluid (CSF) biomarkers can predict future development of Alzheimer Disease (AD) dementia within 10 years in patients with mild cognitive impairment (MCI).

The CSF biomarkers, total tau (T-tau), phosphorylated tau (P-tau), and β-amyloid 1-42 (Aβ42), have been compared for their ability to distinguish between early and late converters to AD.

Scientists at Skåne University (Malmö; Sweden) carried out an extended follow-up of the cohort from a previous study involving 137 patients with mild cognitive impairment (MCI) at baseline for an average follow-up period of 9.2 years. Lumbar punctures were performed at base line and during follow up on the 137 patients and 39 human volunteers. They analyzed CSF concentrations of Aβ42, T-tau, and phosphorylated tau P-tau181 using xMAP technology.

Systems using xMAP technology (Luminex; Austin, TX, USA) perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. The results of the study showed an equal reduction in baseline CSF Aβ42 levels in patients with MCI who converted to AD within five years, the early converters, compared with those who converted later, such as between five and 10 years, whilst T-tau and P-tau levels were substantially higher in early converters compared to later ones. As many as 91% of the patients with mild memory impairment who had these risk markers went on to develop Alzheimer's within a ten-year period. In contrast, those who had memory impairment but normal values for the markers did not run a higher risk of getting Alzheimer's than healthy individuals

By observing how the levels of the biomarkers develop over the ten years before the patient's diagnosis, the scientists have also been able to map the progression of the disease in the brain. The results indicate that it starts with a modified turnover of beta-amyloid. Only later is this followed by changes in the tau protein and damage to nerve cells. This can be important information for those developing new therapies for Alzheimer's. Senior author of the study Oskar Hansson, MD, PhD, said, "This is a very important finding with regard to the development of new therapies against the disease. All prospective therapies have so far shown to be ineffective in stopping the disease, and many people are concerned that the pharmaceutical companies will give up their efforts in this field." The study was published in the January 2012 edition of the Archives of General Psychiatry.

Related Links:

Skåne University
Luminex


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.